Dydrogesterone support in threatened miscarriage

Maturitas

Volumn 65, Issue SUPPL. 1, 2009, Pages

  El Zibdeh, Mazen Y ^a   Yousef, Lama T ^a  

^a Islamic Hospital   (Jordan)

Author keywords

Bleeding; Dydrogesterone; Pregnancy; Progestogen; Threatened miscarriage

Indexed keywords

DYDROGESTERONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; TREATMENT DURATION; VAGINA BLEEDING;

ABORTION, SPONTANEOUS; ABORTION, THREATENED; ADULT; CONGENITAL ABNORMALITIES; DYDROGESTERONE; FEMALE; HUMANS; INCIDENCE; PREGNANCY; PREGNANCY COMPLICATIONS; PROGESTINS; REPRODUCTIVE CONTROL AGENTS; YOUNG ADULT;

EID: 72649101942     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.11.013     Document Type: Article

References (38)

1. Lok I.H., and Neugebauer R. Psychological morbidity following miscarriage. Best Pract Res Clin Obstet Gynaecol 21 (2007) 229-247
2. Weiss J.L., Malone F.D., Vidaver J., et al. Threatened abortion: a risk factor for poor pregnancy outcome, a population-based screening study. Am J Obstet Gynecol 190 (2004) 745-750
3. Regan L., Braude P.R., and Trembath P.L. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 299 (1989) 541-545
4. Stirrat G.M. Recurrent abortion: definition and epidemiology. Lancet 336 (1990) 673-675
5. Greene M.F. Spontaneous abortions and major malformations in women with diabetes mellitus. Semin Reprod Endocrinol 17 (1999) 127-136
6. Wang J.X., Norman R.J., and Wilcox A.J. Incidence of spontaneous abortion among pregnancies produced by assisted reproductive technology. Hum Reprod 19 (2004) 272-277
7. Warren J.E., and Silver R.M. Genetics of pregnancy loss. Clin Obstet Gynecol 51 (2008) 84-95
8. Slama R., Bouyer J., Windham G., Fenster L., Werwatz A., and Swan S.H. Influence of paternal age on the risk of spontaneous abortion. Am J Epidemiol 161 (2005) 816-823
9. de la Rochebrochard E., and Thonneau P. Paternal age and maternal age are risk factors for miscarriage; results of a multicentre European study. Hum Reprod 17 (2002) 1649-1656
10. Simpson J.L., Mills J.L., Holmes L.B., et al. Low fetal loss rates after ultrasound-proved viability in early pregnancy. JAMA 258 (1987) 2555-2557
11. Dogra V., Paspulati R.M., and Bhatt S. First trimester bleeding evaluation. Ultrasound Q 21 (2005) 69-85
12. Basama F.M., and Crosfill F. The outcome of pregnancies in 182 women with threatened miscarriage. Arch Gynecol Obstet 270 (2004) 86-90
13. Karim S.A., Bakhtawar I., Butta A.T., and Jalil M. Effects of first and second trimester vaginal bleeding on pregnancy outcome. J Pak Med Assoc 48 (1998) 40-42
14. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 315 (1997) 32-34
15. Sotiriadis A., Papatheodorou S., and Makrydimas G. Threatened miscarriage: evaluation and management. BMJ 329 (2004) 152-155
16. Szabo I., and Szilagyi A. Management of threatened abortion. Early Pregnancy 2 (1996) 233-240
17. Griebel C.P., Halvorsen J., Golemon T.B., and Day A.A. Management of spontaneous abortion. Am Fam Phys 72 (2005) 1243-1250
18. Aleman A., Althabe F., Belizán J., and Bergel E. Bed rest during pregnancy for preventing miscarriage. Cochrane Database Syst Rev 2 (2005) 10.1002/14651858.CD003576
19. Wahabi H.A., Abed Althagafi N.F., and Elawad M. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 3 (2007) CD005943
20. Qureshi N.S., Edi-Osagie E.C., Ogbo V., Ray S., and Hopkins R.E. First trimester threatened miscarriage treatment with human chorionic gonadotrophins: a randomised controlled trial. BJOG 112 (2005) 1536-1541
21. Norman T.R., Morse C.A., and Dennerstein L. Comparative bioavailability of orally and vaginally administered progesterone. Fertil Steril 56 (1991) 1034-1039
22. Schindler A.E., Campagnoli C., Druckmann R., et al. Classification and pharmacology of progestins. Maturitas 46 Suppl. 1 (2003) S7-16
23. Omar M.H., Mashita M.K., Lim P.S., and Jamil M.A. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol 97 (2005) 421-425
24. Pelinescu-Onciul D. Subchorionic hemorrhage treatment with dydrogesterone. Gynecol Endocrinol 23 Suppl. 1 (2007) 77-81
25. Kalinka J., and Szekeres-Bartho J. The impact of dydrogesterone supplementation on hormonal profile and progesterone-induced blocking factor concentrations in women with threatened abortion. Am J Reprod Immunol 53 (2005) 166-171
26. Czajkowski K., Sienko J., Mogilinski M., Bros M., Szczecina R., and Czajkowska A. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril 87 (2007) 613-618
27. El-Zibdeh M.Y. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol 97 (2005) 431-434
28. Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev 85 (2009) 375-377
29. Critchley H.O., Jones R.L., Lea R.G., et al. Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. J Clin Endocrinol Metab 84 (1999) 240-248
30. Lea R.G., and Clark D.A. Macrophages and migratory cells in endometrium relevant to implantation. Baillieres Clin Obstet Gynaecol 5 (1991) 25-59
31. Szekeres-Bartho J., Wilczynski J.R., Basta P., and Kalinka J. Role of progesterone and progestin therapy in threatened abortion and preterm labour. Front Biosci 13 (2008) 1981-1990
32. Szekeres-Bartho J., Barakonyi A., Par G., Polgar B., Palkovics T., and Szereday L. Progesterone as an immunomodulatory molecule. Int Immunopharmacol 1 (2001) 1037-1048
33. Polgár B., Nagy E., Mikó E., Varga P., and Szekeres-Barthó J. Urinary progesterone-induced blocking factor concentration is related to pregnancy outcome. Biol Reprod 71 (2004) 1699-1705
34. Raghupathy R., Al Mutawa E., Makhseed M., Azizieh F., and Szekeres-Bartho J. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG 112 (2005) 1096-1101
35. Raghupathy R., Al Mutawa E., Makhseed M., Al-Azemi M., and Azizieh F. Redirection of cytokine production by lymphocytes from women with pre-term delivery by dydrogesterone. Am J Reprod Immunol 58 (2007) 31-38
36. Orsal A.S., Blois S., Labuz D., Peters E.M., Schaefer M., and Arck P.C. The progesterone derivative dydrogesterone down-regulates neurokinin 1 receptor expression on lymphocytes, induces a Th2 skew and exerts hypoalgesic effects in mice. J Mol Med 84 (2006) 159-167
37. Blois S.M., Joachim R., Kandil J., et al. Depletion of CD8+ cells abolishes the pregnancy protective effect of progesterone substitution with dydrogesterone in mice by altering the Th1/Th2 cytokine profile. J Immunol 172 (2004) 5893-5899
38. Joachim R., Zenclussen A.C., Polgar B., et al. The progesterone derivative dydrogesterone abrogates murine stress-triggered abortion by inducing a Th2 biased local immune response. Steroids 68 (2003) 931-940